Michael became President and CEO of Neptune Wellness Solutions in July 2019. Michael is the founder of Random Occurrence, a venture capital and private equity firm. He invested in and cofounded Schmidt’s Naturals, one of the world’s fastest growing wellness brands, leading it from fledgling start-up to acquisition in 2017 by Unilever and onto record breaking growth in 2018. He remained CEO of Schmidt’s Naturals until June 2019, leading its rapid expansion into new and innovative products, retailers and global markets.
Michael is a new breed of unconventional CEO with a personal mission to invest and scale companies globally that will make sustainable innovation and modern wellness solutions accessible to the world. He believes that natural products are the future and that every person deserves natural products that work and minimize their harm to people, the planet and animals.
Through all his investments, Michael is looking toward future technologies, including AI and machine learning to create stronger connections and personalized products for customers. He is a passionate advocate for plant-based solutions a leader for sustainability and has pushed for an end to animal testing in cosmetics. Raised in New York, Michael’s dyslexia made school challenging, but that perspective allowed him to identify opportunities others missed. He became a technology and marketing wunderkind by his mid-teens. He rapidly gained a reputation as an innovative entrepreneur, creating $85 million in revenue by his twenties.
David Mayers brings to Neptune 30 years of senior level executive leadership experience and expertise in Corporate Strategy execution, M&A implementation, R&D, Quality, Supply Chain, Operations and Facility Expansion across several industries, including cannabis extraction, pharmaceuticals, healthcare, and health and wellness. David previously served as Chief Operating Officer of MediPharm Labs Inc., a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction where he was responsible for strategic direction and daily operation of the organization, including direct responsibility of Manufacturing, HR, R&D, IT, Security, Quality, Project Management, Procurement and Supply Chain. Prior to MediPharm, he served as Chief Executive Officer and Chief Operating Officer of Impopharma Inc., a specialty generic pharmaceutical company developing innovative nasal and pulmonary inhalation products for the U.S. market, where he was responsible for strategic direction and operation of the organization. David previously served as President of WellSpring Pharma Services, a division of WellSpring Pharmaceuticals, as well as Vice President of Operations and Director of Quality Control at Purdue Pharma.
Dr. Toni Rinow is well known for accelerating revenue streams through acquisitions, corporate development, sales and marketing, and financings in the global healthcare and consumer product markets. Her professional career has included leadership roles in both public and private pharmaceutical and consumer product organizations, where she spearheaded acquisitions across Canada, Latin America, and India.
Toni has successfully facilitated the negotiation of international corporate alliances valued over $100M and overseen a life science investment portfolio with $400M under management. She held the position of General Manager of Jubilant DraxImage, a global leader in nuclear medicine with over $250M in sales in over 22 countries.
Toni has a keen interest in robotics, natural language processing and machine learning especially with a focus on the retail consumer markets and was trained at Massachusetts Institute of Technology (MIT). In addition to her double Masters in Business Administration (MBA) and Accounting from McGill University, she holds a doctorate in physical chemistry from the Université de Montréal (Ph.D), and a chemical engineering degree from the European Higher Institute of Chemistry in Strasbourg, France. Dr. Rinow believes in giving back to the community and sits on the Board of Directors of several non-for profit organizations.
Scott Antony joined Neptune in 2020 to lead Neptune's brand retail strategy to expand retail distribution and increase sales of the Company's consumer-facing brands. Scott previously worked at Unilever North America where he has held a variety of senior leadership positions since joining the company in 1986. Throughout his career at Unilever, he led the company's most profitable businesses, consistently outperforming competitors, surpassing targets, and achieving multi-million-dollar gains while attaining significant market growth. Most recently, Scott served as VP of Sales for Unilever's Target Division, where he developed and managed the company's Target relationship. In this role, he led a complete business turnaround doubling Unilever's sales with Target while achieving continuous market share growth. Prior, Scott led Unilever's Safeway Division, where he established a sales team from the ground up and supervised, trained, and mentored a team of 25 top performers responsible for sales, supply chain, shopper marketing, business development, category management, digital and e-commerce, category insights and customer service.
François-Karl joined Neptune in 2016 as Vice-President, Scientific Affairs following the acquisition of Biodroga Nutraceuticals. He was appointed to Vice President Science and Innovation of Neptune’s Nutrition Business in 2017, where he oversees research and development, product development and quality assurance programs. He began his career in 2001 as a research Chemist for a Quebec-based pharmaceutical company. In 2005, he transitioned into the Natural Health Product industry as the Director, Scientific Affairs for Biodroga and later on as Vice President, where he was instrumental in the company’s growth. François-Karl holds a master’s degree in organic chemistry from Université de Montréal.
Graham joined Neptune as Chief Scientific Officer in 2019. He leads the corporation’s clinical programs, research and development strategy and product development efforts to deliver high quality differentiated products to the global natural product and legal cannabis industries. Graham has twenty years of clinical research experience, including as Chief R&D Officer at Altasciences, where he was responsible for developing innovative nonclinical and clinical techniques and overseeing the clinical pharmacology study designs. He was also Chief Executive Officer at Manna Research, which he grew from a single clinical research site to the largest family practice site network in Canada. As President at Cetero Research, he was responsible for the early and late stage clinical development conducted at the Cetero facilities in Toronto and Miami. He holds a PhD in neurology and neurosurgery from McGill University and worked as a Fellow at the National Institute of Health.
Jackie joined Neptune in 2014 as Director, Sales. With close to 20 years of combined nutraceutical and healthcare sales experience, she has been integral to the execution of global strategies and development of new markets. In 2017, she was promoted to the role of Vice-President Business Development where she plays a strategic role in the commercialization of the company’s products and services. Prior to joining Neptune, Jackie held several key positions in global companies, including 3M Canada. She graduated from the Faculty of Medicine at Université de Montréal in 2001 with a science degree specializing in nutrition and earned a graduate degree in management from HEC Montréal. She also holds an EMBA from Concordia University.
Jean-Daniel joined Neptune as Director, Corporate Affairs in November 2012 and has been acting as Secretary of the Board since June 2014. Appointed Vice-President Legal Affairs, in June 2017, he is in charge of all legal and corporate law matters. A 2018 finalist for Quebec General Counsel of the Year – Small/Mid-Cap Companies, and a finalist at the 2015 Canadian General Counsel Awards as “Leader of Tomorrow”, he holds a law degree from Université de Montréal (2005) and has been a member of the Quebec Bar since 2006. Prior to joining the Neptune, Jean-Daniel was a partner in a Montreal boutique securities law firm, where he practised in the areas of mergers and acquisitions, corporate finance and securities, and general corporate and commercial law. He is also a member of the Board of Québec Bourse, a non-profit organization promoting public market access in Quebec.
Marc joined the company in 2016 as Vice President Sales, following the acquisition of Biodroga Nutraceuticals. In 2018, he became responsible for the global sales of Neptune’s Nutrition Business and now oversees the entire nutrition sales team. His career in the health and nutrition industry began over 25 years ago in consumer health brands. He also has experience working with Bioriginal Corporation and an ecommerce company specialized in Omega-3. In 2009, Marc became Vice-President Sales of Biodroga, where he largely contributed to the growth of the company. He studied commerce at Concordia University.
Melody joined Neptune in 2015 as Director Scientific and Regulatory Affairs. With over 18 years of experience in the food and dietary supplement industries, her current contributions to the Neptune team include overseeing regulatory initiatives and leading scientific research and innovation. Prior to joining Neptune, Melody held director positions at the multinational nutritional product and ingredient manufacturing companies, Herbalife and Aker BioMarine, and gained pertinent expertise in toxicology and global regulatory affairs during her 10-year role as a consultant to the food and nutrition industry. She has published in well-respected scientific journals, served on boards of directors and chaired and participated in various committees for several industry trade associations. Melody earned her Bachelor of Science degree in biomedical toxicology from the University of Guelph and her Master of Science degree in European food regulatory affairs from the University of Ulster.
Michel plays an essential role in helping position the company in business segments characterized by larger size and growth. During his 16-year career at Neptune, he has held a variety of positions, including Chairman of the Board of Directors from 2000-2008 and Vice-President Business Development where he was instrumental in the company’s early development and growth by helping create a new nutrition products category, Omega-3 krill oil. His entrepreneurial drive led him to build a start-up venture in residential construction components. He previously worked for large corporations, including Armstrong World Industries and Reichhold Chemicals, where he held senior management business development positions. Michel also had a political career, during which he was active as alderman for 20 years for one of the largest cities in Quebec. He holds a Bachelor of Commerce degree from Concordia University.
Paola joined the company as Director Human Resources, in 2019. Her main responsibilities include the alignment of corporate structures, processes, programs and policies related to human resources, to achieve the company's objectives, as well as employee engagement. Paola combines more than 15 years of experience in human resources and has successfully translated corporate strategies into operational HR action plans in different industries, including aerospace and renewable energy. Paola holds a bachelor's degree in sociology from the Université du Québec à Montréal (1998) and has been a member of the Ordre des conseillers en ressources humaines agréés du Québec since 2003.
Stephen oversees all of Neptune’s extraction, manufacturing and packaging operations at the company’s two facilities, Sherbrooke, Quebec and Conover, North Carolina. He has over 30 years of experience in quality assurance and overseeing all aspects of pharmaceutical and nutritional supplement manufacturing operations. His wide-ranging experience includes positions with global companies, supervising over 1000 employees, managing rapid capacity expansions and holding responsibilities with several manufacturing facilities in various countries. He has also been involved with comprehensive cGMP and FDA regulatory programs and standards.